Literature DB >> 31377467

Anti-inflammatory and antiviral effects of minocycline in enterovirus 71 infections.

Yu-Ting Liao1, Shih-Min Wang2, Shun-Hua Chen3.   

Abstract

Enterovirus 71 (EV71) brainstem encephalitis (BE) is divided into-uncomplicated BE, autonomic nervous system (ANS) dysregulation, and pulmonary edema (PE)-based on cytokine-mediated severe systemic and central nervous system (CNS) inflammatory responses. Minocycline has been found to have anti-inflammatory and immunomodulatory properties in infectious and inflammatory neurological disease models. The effects of minocycline on EV71 infection were studied in vitro and in vivo experiments. The minocycline treatment (100-300 μg/mL) on cytokine expressions and viral replications were investigated in rhabdomyosarcoma (RD), U-87MG, and THP-1 cells. The mouse-adapted-EV71 strain (MP4)-infected 7-day-old ICR mice model was used to explore the anti-inflammatory and antiviral effects of minocycline (1 and 5 μg/g) for the treatment of EV71 infection. In in vitro, minocycline reduced cytopathic effects (CPEs), viral protein expressions, viral titers, the levels of interleukin (IL)-6 and IL-8 and relative mRNA expressions of IL-12p40, IL-1β, and tumor necrosis factor (TNF) after EV71 infection. The levels of TNF, IL-1β, IL-6, and IL-8 decreased with a single dose of minocycline in EV71-infected THP-1 cells. Double-dose minocycline treatment demonstrated more effective reduction in cytokines. In the MP4-infected animal model, clinical scores, mortality rates and viral titers in various brain tissues were decreased evidently after double-dose minocycline treatment. Minocycline inhibited IL-6 and granulocyte colony-stimulating factor (G-CSF) in plasma and TNF in the cerebellum. Minocycline has properties that enable it to function both as an anti-inflammatory and antiviral agent in EV71 infection. These results evidence its potential usefulness in clinical treatment.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Anti-inflammatory agent; Antiviral effect; Enterovirus 71; Minocycline; Minocycline hydrochloride (PubChem CID: 54685925); Phorbol 12-myristate 13-acetate (PubChem CID: 27924); Systemic inflammatory response

Year:  2019        PMID: 31377467     DOI: 10.1016/j.biopha.2019.109271

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

Review 1.  Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19.

Authors:  Ahmed S Ali; Mai A ASattar; Shahid Karim; Dina Kutbi; Hanin Aljohani; Duaa Bakhshwin; Mohammed Alsieni; Huda M Alkreathy
Journal:  Arab J Chem       Date:  2021-01-10       Impact factor: 5.165

2.  Antiviral Activity of a Llama-Derived Single-Domain Antibody against Enterovirus A71.

Authors:  Peng-Nien Huang; Hsiang-Ching Wang; Hui-Chen Hung; Sung-Nien Tseng; Teng-Yuan Chang; Min-Yuan Chou; Yu-Jen Chen; Yun-Ming Wang; Shin-Ru Shih; John Tsu-An Hsu
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

3.  Doxycycline as a potential partner of COVID-19 therapies.

Authors:  Alexandre E Malek; Bruno P Granwehr; Dimitrios P Kontoyiannis
Journal:  IDCases       Date:  2020-06-06

Review 4.  Tetracycline and viruses: a possible treatment for COVID-19?

Authors:  Jesús A Mosquera-Sulbaran; Hugo Hernández-Fonseca
Journal:  Arch Virol       Date:  2020-11-02       Impact factor: 2.574

Review 5.  The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19.

Authors:  Mahda Delshad; Naeimeh Tavakolinia; Atieh Pourbagheri-Sigaroodi; Ava Safaroghli-Azar; Nader Bagheri; Davood Bashash
Journal:  Int Immunopharmacol       Date:  2021-03-18       Impact factor: 5.714

Review 6.  The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.

Authors:  Esmé Jansen van Vuren; Stephan F Steyn; Christiaan B Brink; Marisa Möller; Francois P Viljoen; Brian H Harvey
Journal:  Biomed Pharmacother       Date:  2021-01-01       Impact factor: 6.529

Review 7.  Integrating heterogeneous data to facilitate COVID-19 drug repurposing.

Authors:  Lucía Prieto Santamaría; Marina Díaz Uzquiano; Esther Ugarte Carro; Nieves Ortiz-Roldán; Yuliana Pérez Gallardo; Alejandro Rodríguez-González
Journal:  Drug Discov Today       Date:  2021-10-16       Impact factor: 7.851

Review 8.  Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.

Authors:  Leena Abdulaziz; Esraa Elhadi; Ejlal A Abdallah; Fadlalbaseer A Alnoor; Bashir A Yousef
Journal:  J Exp Pharmacol       Date:  2022-03-08

9.  Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.

Authors:  Y C Tsai; T F Tsai
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-09-03       Impact factor: 5.346

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.